Sources

The studies and labels cited on these pages.

All sources

U.S. Food and Drug Administration. FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T Cell Immunotherapies. June 26, 2025. fda.gov
Regulatory Affairs Professionals Society. FDA eliminates REMS for approved CAR-T therapies. June 30, 2025. raps.org
Belousova A, Brown R, Peel A. Employers' top four questions about cell and gene therapies. Mercer. August 13, 2025. mercer.com
Midwest Business Group on Health. Employer survey release. September 9, 2026 (47 employer members). PDF
Midwest Business Group on Health. Employer Survey on Cell & Gene Therapies. June 2026 (53 employers). PDF
Employee Benefit Research Institute. Cell and Gene Therapies in Employment-Based Health Insurance: Financing the High-Cost, High-Impact Future. Issue Brief. February 12, 2026. ebri.org
Prescribing information for approved CAR-T cell therapies, section 2.2. DailyMed, U.S. National Library of Medicine. Accessed November 6, 2026. dailymed.nlm.nih.gov
Buck S, Akers RK, Kordella R. Cell & gene therapy: Preparing for the next phase of employer health plan risk. Lockton. June 30, 2026. lockton.com
Worth T. Gene therapy: Rarely needed but massively expensive. Leader’s Edge (Council of Insurance Agents & Brokers). April 30, 2025. leadersedge.com
U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Cellular & Gene Therapy Products. fda.gov
U.S. Food and Drug Administration. What is Gene Therapy? fda.gov
U.S. Food and Drug Administration. Approved Cellular and Gene Therapy Products. Content current as of October 30, 2026. fda.gov
National Cancer Institute. CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers. Updated February 26, 2025. cancer.gov